OraSure Technologies (NASDAQ: OSUR) reported Q2 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $30.4 million versus the consensus estimate of $28.95 million.

"We are pleased with the record level of revenues reported for the second quarter of 2015 as well as our bottom line results," said Douglas A. Michels, President and CEO of OraSure Technologies. "Our molecular collection systems business continues the high performance level we have seen in recent quarters and our HCV business continues to grow nicely. We are also making good progress in our efforts to fund and commercialize a rapid Ebola test on our OraQuick® platform. With the first half of the year now complete, I believe we are well positioned to deliver solid growth and full year profitability for 2015."

For earnings history and earnings-related data on OraSure Technologies (OSUR) click here.